β-Sheet-breaking peptides inhibit the fibrillation of human α-synuclein

Biochemical and Biophysical Research Communications

Volumn 387, Issue 4, 2009, Pages 682-687

  Kim, You Soon ^a   Lim, Dongyeol ^a   Kim, Joo Yeon ^a   Kang, Shin Jung ^a   Kim, Yang Hee ^a   Im, Hana ^a  

^a Sejong University   (South Korea)

Author keywords

Synuclein; Conformational switch; Peptide inhibitors; Protein amyloid; Protein fibrils

Indexed keywords

ALPHA SYNUCLEIN; HEXAPEPTIDE; PROLYLGLYCYLVALYLTHREONYLALANYLVALINE; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; BETA SHEET; DISSOLUTION; HUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; SEQUENCE ANALYSIS;

ALPHA-SYNUCLEIN; AMINO ACID SEQUENCE; ANTIPARKINSON AGENTS; DRUG DESIGN; HUMANS; OLIGOPEPTIDES; PROTEIN STRUCTURE, SECONDARY;

EID: 68549139858     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2009.07.083     Document Type: Article

References (27)

1. Goetz C.G. Charcot and Parkinson's disease. In: Factor S., and Weiner W. (Eds). Parkinson's Disease Diagnosis and Clinical Management (2002), Demos Medical Publishing, New York 19-26
2. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., Stenroos E.S., Chandrasekharappa S., Athanassiadou A., Papapetropoulos T., Johnson W.G., Lazzarini A.M., Duvoisin R.C., Di Iorio G., Golbe L.I., and Nussbaum R.L. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 276 (1997) 2045-2047
3. Kruger R., Kuhn W., Muller T., Woitalla D., Graeber M., Kosel S., Przuntek H., Epplen J.T., Schols L., and Riess O. Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease. Nat. Genet. 18 (1998) 106-108
4. Zarranz J.J., Alegre J., Gomez-Esteban J.C., Lezcanno E., Ros R., Ampuero I., Vidal L., Hoenicka J., Rodriguez O., Atares B., Llorens V., Gome Z., Tortosa E., Del Ser T., Munoz D.G., and de Yebenex J.G. The new mutation, E46K, of α-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 55 (2004) 164-173
5. Conway K.A., Lee S.-J., Rochet J.-C., Ding T.T., Williamson R.E., and Lansbury Jr. P.T. Acceleration of oligomerization, not fibrillization, is a shared property of both α-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc. Natl. Acad. Sci. USA 97 (2000) 571-576
6. Choi W., Zibaee S., Jakes R., Serpell L.C., Davletov B., Crowther R.A., and Goedert M. Mutation E46K increases phospholipid binding and assembly into filaments of human α-synuclein. FEBS Lett. 576 (2004) 363-368
7. Singleton A.B., Farrer M., Johnson J., Singleton A., Haque S., Lachergus J., Hulihan M., Perualinna T., Dutra A., Nussbaum R., Lincoln S., Crawley A., Hanson M., Miller D., Blancato J., Hardy J., and Grinn-Hardy K. Α-Synuclein locus triplication causes Parkinson's disease. Science 302 (2003) 841
8. Charitier-Harlin M.C., Kachergus J., Roumier C., Mouroux V., Douay X., Lincoln S., Levecque C., Larvor L., Andrieux J., Hulihan M., Waucquier N., Defebvre L., Amouyel P., Farrer M., and Destee A. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 364 (2004) 1167-1169
9. Ibanez P., Bonnet A.M., Debarges B., Lohmann E., Tison F., Pollak P., Agid Y., Durr A., and Brice A. Causal relation between α-synuclein gene duplication and familial Parkinson's disease. Lancet 364 (2004) 1169-1171
10. Feany M.B., and Bender W.W. A Drosophila model of Parkinson's disease. Nature 404 (2000) 394-398
11. Masliah E., Rockenstein E., Veinbergs I., Mallory M., Hashimoto M., Takeda A., Sagara Y., Sisk A., and Mucke L. Dopaminergic loss and inclusion body formation in α-synuclein mice. implications for neurodegenerative disorders. Science 287 (2000) 1265-1269
12. Rochet J.C., and Lansbury Jr. P.T. Amyloid fibrillogenesis: themes and variations. Curr. Opin. Struct. Biol. 10 (2000) 60-68
13. Koo E.H., Lansbury Jr. P.T., and Kelly J.W. Amyloid diseases: abnormal protein aggregation in neurodegeneration. Proc. Natl. Acad. Sci. USA 96 (1999) 9989-9990
14. Ono K., and Yamada M. Antioxidant compounds have potent anti-fibrillogenic and fibril-destabilizing effects for α-synuclein fibrils in vitro. J. Neurochem. 97 (2006) 105-115
15. Ono K., Yoshiike Y., Takashima A., Hasegawa K., Kaike H., and Yamada M. Potent anti-amyloidogenic and fibril-destabilizing effects of polyphenols in vitro: implications for the prevention and therapeutics of Alzheimer's disease. J. Neurochem. 87 (2003) 172-181
16. Wetzel R. For protein misassembly, it's the "I" decade. Cell 86 (1996) 699-702
17. Speed M.A., Wang D.I., and King J. Specific aggregation of partially folded polypeptide chains: the molecular basis of inclusion body composition. Nat. Biotechnol. 14 (1996) 1283-1287
18. Tjiernberg L.O., Naslund J., Lindqvist F., Johansson J., Karlstrom A.R., Thyberg J., Jerenius L., and Nordstedt C. Arrest of β-amyloid fibril formation by a pentapeptide ligand. J. Biol. Chem. 271 (1996) 8545-8548
19. Soto C., Kascsak R.J., Saborio G.P., Aucouturier P., Wisniewski T., Prelli F., Kascsak R., Mendez E., Harris D.A., Ironside J., Tagliavini F., Carp R.I., and Frangione B. Reversion of prion protein conformational changes by synthetic β-sheet breaker peptides. Lancet 355 (2000) 192-197
20. Soto C., Sigurdsson E.M., Morelli L., Kumar R.A., Castano E.M., and Frangione B. β-Sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: Implications for Alzheimer's therapy. Nat. Med. 7 (1998) 822-826
21. Permanne B., Adessi C., Saborio G.P., Fraga S., Frossard M.J., Van Dorpe J., Dewachter I., Banks W.A., Van Leuven F., and Soto C. Reduction of amyloid load and cerebral damage in transgenic mouse model of Alszheimer's disease by treatment with β-sheet breaker peptide. FASEB J. 16 (2002) 860-862
22. Wood S.J., Wypych J., Steavenson S., Louis J.C., Citron M., and Biere A.L. Synuclein fibrillogenesis is nucleation-dependent: implications for the pathogenesis of Parkinson's disease. J. Biol. Chem. 274 (1999) 19509-19512
23. Koo H.-J., Lee H.-J., and Im H. Sequence determinants regulating fibrillation of human α-synuclein. Biochem. Biophys. Res. Commun. 368 (2008) 772-778
24. Koo H.-J., Choi M.-Y., and Im H. Aggregation-defective α-synuclein mutants inhibit the fibrillation of Parkinson's disease-linked α-synuclein variants. Biochem. Biophys. Res. Commun. 386 (2009) 165-169
25. Volles M.J., and Lansbury Jr. P.T. Zeroing in on the pathogenic form of α-synuclein and its mechanism of neurotoxicity in Parkinson's disease. Biochemistry 42 (2003) 7871-7878
26. Giasson B.I., Murray I.V.J., Trojanowski J.Q., and Lee V.M.-Y. A hydrophobic stretch of 12 amino acid residues in the middle of α-synuclein is essential for filament assembly. J. Biol. Chem. 276 (2001) 2380-2386
27. Bodles A.M., Guthrie D.J.S., Harriott P., Campbell P., and Irvine G.B. Toxicity of non-Aβ component (NAC) of Alzheimer's disease amyloid, and N-terminal fragment thereof, correlates to formation of β-sheet structure and fibrils. Eur. J. Biochem. 267 (2000) 2186-2194